BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
BioStem Technologies (OTC: BSEM) announced that its Audit Committee approved the appointment of KPMG LLP as its independent registered public accounting firm, ending its engagement with Marcum (now CBIZ) effective Oct 22, 2025. The company said KPMG was selected for its life sciences expertise to support BioStem's growth and planned uplist to Nasdaq following completion of full-year 2024 and 2025 audits. Management emphasized the uplisting as a priority to improve liquidity, visibility, and market valuation. The company also stated there were no disagreements with Marcum during the two most recent fiscal years and any interim period before the dismissal.
BioStem Technologies (OTC: BSEM) ha annunciato che il suo Audit Committee ha approvato la nomina di KPMG LLP come sua società di revisione indipendente registrata, ponendo fine all'impegno con Marcum (ora CBIZ) con effetto 22 ottobre 2025. L'azienda ha detto che KPMG è stata scelta per la sua esperienza nel settore delle scienze della vita per supportare la crescita di BioStem e il previsto uplisting sul Nasdaq dopo il completamento delle verifiche contabili relative agli anni fiscali 2024 e 2025. La dirigenza ha sottolineato l'uplisting come priorità per migliorare la liquidità, la visibilità e la valutazione di mercato. L'azienda ha anche dichiarato che non vi sono disaccordi con Marcum durante i due anni fiscali più recenti e in eventuali periodi intermedi prima della risoluzione.
BioStem Technologies (OTC: BSEM) anunció que su Comité de Auditoría aprobó la designación de KPMG LLP como su firma independiente de contabilidad registrada, poniendo fin a su relación con Marcum (ahora CBIZ) a partir del 22 de octubre de 2025. La empresa dijo que KPMG fue seleccionada por su experiencia en ciencias de la vida para apoyar el crecimiento de BioStem y el uplisting a Nasdaq previsto tras completar las auditorías anuales 2024 y 2025. La dirección enfatizó que el uplisting es una prioridad para mejorar la liquidez, la visibilidad y la valoración del mercado. La compañía también declaró que no existían desacuerdos con Marcum durante los dos años fiscales más recientes y cualquier periodo interino anterior a la desvinculación.
BioStem Technologies (OTC: BSEM)는 감사위원회가 독립 등록 공인회계법인으로 KPMG LLP의 임명을 승인했다고 발표했다. 이는 Marcum(현재 CBIZ)과의 약정을 2025년 10월 22일부로 종료하는 것을 의미한다. 회사는 KPMG를 생명과학 분야 전문성으로 선택해 BioStem의 성장과 전체 연도 2024 및 2025 감사 완료 후 나스닥으로의 상장을 지원할 것이라고 말했다. 경영진은 유동성, 가시성, 시장 평가를 개선하기 위한 상장을 우선순위로 강조했다. 또한 최근 두 회계연도와 해석기 간의 중간 기간 동안 Marcum과의 이견이 없었다고 밝혔다.
BioStem Technologies (OTC: BSEM) a annoncé que son comité d'audit a approuvé la nomination de KPMG LLP en tant que cabinet d'audit indépendant enregistré, mettant fin à son engagement avec Marcum (désormais CBIZ) à compter du 22 octobre 2025. L'entreprise a déclaré que KPMG avait été choisie pour son expertise dans les sciences de la vie afin de soutenir la croissance de BioStem et le prochain uplisting vers le Nasdaq après l'achèvement des audits annuels 2024 et 2025. La direction a souligné que l'up-listing est une priorité pour améliorer la liquidité, la visibilité et l'évaluation du marché. L'entreprise a également indiqué qu'il n'y avait pas de désaccords avec Marcum au cours des deux exercices fiscaux les plus récents et pour toute période intermédiaire avant le licenciement.
BioStem Technologies (OTC: BSEM) gab bekannt, dass der Prüfungsausschuss die Ernennung von KPMG LLP als unabhängige registrierte Wirtschaftsprüfungsgesellschaft genehmigt hat und damit die Zusammenarbeit mit Marcum (jetzt CBIZ) mit Wirkung zum 22. Oktober 2025 beendet. Das Unternehmen sagte, KPMG aufgrund ihrer Expertise im Life-Sciences-Bereich gewählt zu haben, um BioStems Wachstum zu unterstützen und das Up-listing zum Nasdaq nach Abschluss der vollständigen Jahresprüfungen 2024 und 2025 durchzuführen. Das Management hob das Uplisting als Priorität hervor, um Liquidität, Sichtbarkeit und Marktbewertung zu verbessern. Das Unternehmen erklärte außerdem, dass es keine Unstimmigkeiten mit Marcum in den beiden jüngsten Geschäftsjahren und in etwaigen Zwischenzeiten vor der Kündigung gab.
BioStem Technologies (OTC: BSEM) أعلنت لجنة التدقيق لديها أن ترشيح KPMG LLP كمكتب محاسبة مسجل مستقل قد تمت الموافقة عليه، وانهاء تعاقدها مع Marcum (الآن CBIZ) اعتباراً من 22 أكتوبر 2025. وقالت الشركة إن KPMG اختيرت بسبب خبرتها في علوم الحياة لدعم نمو BioStem وللسعي إلى الترقية إلى Nasdaq بعد استكمال تدقيقات السنة المالية 2024 و2025 بشكل كامل. وأكدت الإدارة أن الترقي إلى البورصة يمثل أولوية لتحسين السيولة والرؤية وتقييم السوق. كما ذكرت الشركة أنه لم يكن هناك خلافات مع Marcum خلال عامين ماليين الأخيرين وأي فترة وسيطة قبل الإقالة.
BioStem Technologies (OTC: BSEM) 公告，其审计委员会已批准任命 KPMG LLP 作为独立注册公众会计师事务所，结束与 Marcum（现为 CBIZ）的合作，生效日期为 2025年10月22日。公司表示选择 KPMG 是因为其在生命科学领域的专业知识，以支持 BioStem 的增长，并在完成 2024 和 2025 年完整年度审计后计划 在纳斯达克上市。管理层强调上市是提高流动性、知名度和市场估值的优先事项。公司还表示，在最近两个财政年度及任何临时期间，与 Marcum 之间不存在 分歧。
- KPMG appointment effective Oct 22, 2025
- No disagreements with prior auditor during two most recent fiscal years
- Plans to pursue Nasdaq uplisting after 2024 and 2025 audits
- None.
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the Audit Committee of its Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company's independent registered public accounting firm, and it has ended its engagement with its prior registered independent public accounting firm, Marcum LLP (now known as CBIZ, Inc.) (“Marcum”), effective as of October 22, 2025.
“As we transition to a new audit firm, we would like to thank Marcum for their support and contributions to our financial reporting over the past two years of rapid growth for the Company,” said Brandon Poe, Chief Financial Officer of BioStem. Mr. Poe added, “We conducted a thorough search for a firm to support our long-term growth plans and capital markets strategy, including our planned uplist to Nasdaq, and KPMG was our top choice. We are engaging a firm with a dedicated life sciences team and direct industry experience, and we are confident that KPMG will provide the expertise we require as our organization expands.”
During the Company’s two most recent fiscal years and any subsequent interim period preceding the dismissal, there were no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. Please refer to the Company’s OTC Disclosure & News Service disclosure on October 27, 2025, for additional information.
Nasdaq Uplisting Progress
Following the completion of the full year 2024 and 2025 audits, the Company plans to proceed with its uplisting to the Nasdaq Capital Market.
“We believe we have a clear path toward uplisting, and we continue to make progress building a solid foundation for a national exchange listing,” said Jason Matuszewski, Chairman and Chief Executive Officer of BioStem. “Uplisting remains a key priority that will enable greater visibility for the Company, improve stock liquidity, provide precise market valuation, and increase the Company’s ability to attract top talent. We are pleased to welcome KPMG to support BioStem through this next phase of our corporate evolution.”
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com
FAQ
What did BioStem (BSEM) announce on October 27, 2025 about its auditor?
Why did BioStem (BSEM) choose KPMG as its new auditor?
Will BioStem (BSEM) try to uplist to Nasdaq after changing auditors?
Were there any auditor disagreements reported before BioStem (BSEM) dismissed Marcum?
When did BioStem (BSEM) end its engagement with Marcum (CBIZ)?
